Researchers have engineered gold-based molecules that target cancer cells and leave healthy cells unharmed, in a critical step towards precision cancer drugs with fewer toxic side effects.
Pre-clinical studies have shown the molecules were up to 24 times more effective at killing cancer cells than the widely used anti-cancer drug cisplatin and were also better at inhibiting tumour growth.
The molecules were also more targeted and selective, making them promising candidates for development into a new class of gold-based drugs that can wipe out the cancer without destroying healthy cells.
Significantly, the synthetic molecules are built with resistance-fighting features to keep them effective over time, unlike current chemotherapies.
The study by researchers at RMIT University, detailing four new bio-active molecules and their effectiveness against five types of cancer cells, is published in Chemistry – A European Journal.
Dr Neda Mirzadeh, co-leader of the Molecular Engineering Group at RMIT, said the limitations of commonly used metal-based chemotherapies drove a need to find better alternatives.
“We’ve made huge inroads in cancer treatment over recent decades, but the disease still kills over 9.6 million people globally each year and remains the world’s second leading cause of death,” Mirzadeh said.
“While metal-based drugs have successfully pushed survival rates up, their effectiveness is limited because of toxic side effects, drug resistance and poor stability.
“The gold-based molecules we’ve designed are far more selective and stable.
“Our results show there’s incredible potential here for the development of new cancer-fighting therapeutics that can deliver lasting power and precision.”
The molecules were evaluated in pre-clinical tests and found to be highly cytotoxic against prostate, breast, cervical, melanoma and colon cancer cells. Animal trials showed treatment with the molecules significantly inhibited tumour growth (up to 46.9%, compared with 29% for cisplatin).
The gold-based compounds also inhibit the action of an enzyme found in cancer cells, thioredoxin reductase, that is linked with cancer progression and the development of drug resistance.
In addition, the molecules have strong anti-inflammatory properties, giving them a dual therapeutic effect and potential application in the treatment of chronic inflammatory conditions like arthritis.
Molecular design pioneers
Part of RMIT’s Centre for Advanced Materials and Industrial Chemistry (CAMIC), the Molecular Engineering Group brings together synthetic chemists with pharmacologists and has over two decades of expertise in designing gold molecules for practical applications.
The pioneering group, one of just a few in the world focusing on the medical potential of gold-based molecules, has had two patents awarded for their work to date.
Team leader and CAMIC Director, Distinguished Professor Suresh Bhargava, said gold had an ancient history of medical use, particularly in India and China.
“We know that gold is readily accepted by the human body and we know it has been used for thousands of years in treating various conditions,” Bhargava said.
“Essentially, gold has been market tested, but not scientifically validated.
“Our work is helping both provide the evidence base that’s missing, as well as delivering new families of molecules that are tailor-made to amplify the natural healing properties of gold.”
For Bhargava, who has lost close friends to cancer, the search for new and better treatments is a personal passion.
“I saw friends go through many years of treatment before they died and I saw how the side effects they experienced were almost more painful than the cancer itself,” he said.
“At the time there was no alternative but scientists have recently started to explore the potential of gold-based drugs and I realised this was our opportunity.
“We used the power of collective intelligence to bring together synthetic chemists and pharmacologists to address the issue.”
Bhargava has been invited to join the prestigious International Health Industry Forum and will speak on the gold medicine research at its annual meeting in Yantai, China (20-23 September).
“It’s a big challenge to be solved but all the great medical breakthroughs start from somewhere, and each step brings us closer to our goal of translating our research to make a sustained and lasting impact on the world.”
The research team has completed successful in vitro and in vivo pre-clinical studies and is seeking funding to support the next stage of the research – clinical studies and regulatory approval.
The Latest on: Precision cancer drugs
via Google News
The Latest on: Precision cancer drugs
- City of Hope Scientists Have Developed a Precision Medicine Tool That Predicts If Chemotherapy Will Produce Debilitating Side Effects in Older Adultson January 15, 2021 at 1:22 am
Researchers at City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, have developed a tool that could predict if older ...
- Why cancer cells waste so much energyon January 14, 2021 at 9:25 pm
MIT biologists have found a possible explanation for the Warburg effect, first seen in cancer cells in the 1920s. They found cancer cells use fermentation, an inefficient metabolic pathway, because it ...
- ORION BIOTECHNOLOGY PROJECT AWARDED GRANT TO ADVANCE DRUG DISCOVERYon January 14, 2021 at 8:44 am
Orion Biotechnology Holding SA., a biotechnology company focused on precision engineering small protein therapeutics, today announced that its drug discovery project was awarded funding of CHF 0.9M ...
- Scientists develop approach for exploiting cancer's dietary demandson January 14, 2021 at 8:42 am
Numerous studies in mice and cancer cells have shown cancer growth can be reduced in response to diets lacking serine. But results have been variable because some cancer cells are efficient in making ...
- Treating cancer with precision: It’s time for host response profilingon January 13, 2021 at 8:03 am
Host response can be identified by proteomic profiling, which involves analyzing a broad range of select proteins in a series of patient blood samples, with the first collected prior to treatment and ...
- Scientists identify bacteria-based approach against canceron January 12, 2021 at 10:37 pm
The body's immune system is the first line of defense against infections like bacteria, viruses or cancers. Some cancers, however, have developed the art of molecular deception to avoid destruction by ...
- DarwinHealth Scientists Publish Foundational Research Identifying Regulatory Mechanisms Controlling Cancer Cell States and Drug Responseon January 11, 2021 at 2:58 pm
PRNewswire/ -- DarwinHealth, Inc., a New York-based biotechnology and cancer drug discovery company announces the January 11, 2021 online publication in ...
- Cancer Database Paves the Way for Precision Medicine Therapieson January 11, 2021 at 6:32 am
The database provides a comprehensive characterization of head and neck cancers and could lead to new precision medicine treatments.
- How genetic testing and precision medicine are improving cancer outcomeson January 11, 2021 at 5:52 am
Cancer may not bring DNA and genetics to mind, but all cancer is caused by gene damage. Treatments in the past have typically meant surgery, radiation, or chemotherapy — sometimes all three. Now, ...
- Blueprint Medicines Reports Portfolio Milestones and Outlines 2021 Roadmap for Precision Medicine Leadershipon January 11, 2021 at 5:00 am
PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today provided an update on key portfolio milestones and outlined a strategic roadmap to ...
via Bing News